z-logo
Premium
Epidemiological and clinical features of rosacea in Korea: A multicenter cross‐sectional study
Author(s) -
Lee JeeBum,
Moon Jungyoon,
Moon KiRang,
Yang Ji Hoon,
Kye Young Chul,
Kim Kwang Joong,
Kim Nack In,
Ro Young Suck,
Park Kui Young,
Park Mi Youn,
Song Margaret,
Ahn Kyu Joong,
Ahn Hyo Hyun,
Lee Mi Woo,
Lee Weon Ju,
Choi Yu Sung,
Choi You Won,
Kwon Hyuck Hoon,
Suh Dae Hun
Publication year - 2018
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.14281
Subject(s) - rosacea , epidemiology , medicine , papulopustular , dermatology , cross sectional study , grading (engineering) , pathology , biology , ecology , acne
Rosacea is a common chronic inflammatory skin condition. Although several epidemiological and etiologic studies with large sample sizes have been conducted on Caucasians, such data regarding Asian populations are lacking. A total of 580 patients diagnosed with rosacea were enrolled from October 2014 to February 2015 at 14 general hospitals. Questionnaires, including the standard classification and grading system, were used for evaluation. The average age of the patients was 47.9 years. While 83.8% of patients revealed a single subtype, 16.2% of patients revealed mixed subtypes showing two or more subtypes simultaneously. Erythematotelangiectatic rosacea ( ETR ) was the most prevalent subtype. ETR combined with papulopustular rosacea showed the highest proportion in the mixed subtype group. Mild severity was revealed in 71.9% of patients. The most common aggravating factor was emotional changes (51.7%), followed by stress (48.4%). Approximately half of the patients (47.4%) showed relatively low awareness of rosacea. By identifying the epidemiological and etiologic features in Korea, we can suggest valuable clinical avenues for research, education and awareness among rosacea patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here